Epitopes mapping of SARS-CoV-2 virus to T lymphocytes and Spike protein receptor to B lymphocytes
- Funded by Fundação de Amparo à Pesquisa do Estado de São Paulo [São Paulo Research Foundation] (FAPESP)
- Total publications:1 publications
Grant number: 2020/05256-7
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$71,132.58Funder
Fundação de Amparo à Pesquisa do Estado de São Paulo [São Paulo Research Foundation] (FAPESP)Principal Investigator
PendingResearch Location
BrazilLead Research Institution
Universidade de São PauloResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Subject
Non-Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The emerging SARS-CoV-2 virus appeared in China, with easy spread and significant lethality. In less than three months of its identification it has already caused more than 35,000 deaths worldwide and with an increasing number of fatalities. As it is a new virus introduced in the human population, it is not known if there is an immune population; it has easy spread and lethality varies from 1 to 16% according to country, age group and comorbidities. In the absence of a specific vaccine or treatment, the pandemic is paralyzing entire continents. The entry of all coronaviruses into host cells is known to be mediated by the glycoprotein Spike, a potential therapeutic target, especially the region of the receptor receptor domain. The knowledge of the cellular response to this virus is still little known. Therefore, this knowledge is of immediate relevance. In this project, we aim to map the epitopes of T and B lymphocytes recognized by cells and antibodies of convalescent COVID-19 patients, starting from the complete sequence for T epitopes and focusing on the Spike protein receptor for B lymphocytes. These data may assist in the development of vaccines and immunotherapeutics in the medium term.
Publicationslinked via Europe PMC
Last Updated:3 days ago
View all publications at Europe PMC